

The background of the slide is a microscopic image of muscle tissue, showing characteristic striations. A white rectangular box with rounded corners is centered on the image, containing the title text in blue, all-caps font.

**PUBLIC REPORTING
OF OUTCOMES
OF THE CANCER COMMITTEE**

2016 Quality Improvement Measures

2016 QUALITY IMPROVEMENT MEASURES

Breast conservation surgery rate for women with AJCC clinical stage 0, I, or II breast cancer (Surveillance)

| COMPARISON TO | EPR% | 95% CI | # CASES | # FACILITIES |
|---------------------------|------|-----------|---------|--------------|
| MY CANCER PROGRAM | 77% | 70.3-82.9 | 171 | 1 |
| MY ACS DIVISION | 76% | 75.5-77.5 | 7441 | 88 |
| MY CENSUS REGION | 76% | 75.5-77.5 | 7441 | 88 |
| MY COC PROGRAM TYPE | 66% | 65.2-66.2 | 41003 | 226 |
| MY STATE | 80% | 78.6-81.4 | 3166 | 38 |
| ALL COC APPROVED PROGRAMS | 67% | 66.9-67.5 | 127954 | 1333 |

Image or palpation-guided needle biopsy (core or FNA) of the primary site is performed to establish diagnosis of breast cancer (Quality Improvement)

| COMPARISON TO | EPR% | 95% CI | # CASES | # FACILITIES |
|---------------------------|------|-----------|---------|--------------|
| MY CANCER PROGRAM | 98% | 96-100 | 197 | 1 |
| MY ACS DIVISION | 90% | 89.7-90.9 | 8064 | 88 |
| MY CENSUS REGION | 90% | 89.7-90.9 | 8064 | 88 |
| MY COC PROGRAM TYPE | 89% | 89.2-89.8 | 36793 | 226 |
| MY STATE | 90% | 88.6-90.6 | 3482 | 38 |
| ALL COC APPROVED PROGRAMS | 90% | 90.2-90.6 | 132842 | 1333 |

Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1c or stage IB-III hormone receptor positive breast cancer (Accountability)

| COMPARISON TO | EPR% | 95% CI | # CASES | # FACILITIES |
|---------------------------|------|-----------|---------|--------------|
| MY CANCER PROGRAM | 99% | 96.7-100 | 148 | 1 |
| MY ACS DIVISION | 95% | 94.1-95.3 | 4653 | 88 |
| MY CENSUS REGION | 95% | 94.8-96 | 4653 | 88 |
| MY COC PROGRAM TYPE | 91% | 91.2-91.8 | 25757 | 226 |
| MY STATE | 95% | 94-95.8 | 2098 | 38 |
| ALL COC APPROVED PROGRAMS | 92% | 91.5-91.9 | 79291 | 1333 |

2016 QUALITY IMPROVEMENT MEASURES

Radiation therapy is considered or administered following any mastectomy within 1 year (365 days) of diagnosis of breast cancer for women with ≥ 4 positive regional lymph nodes (Accountability)

| COMPARISON TO | EPR% | 95% CI | # CASES | # FACILITIES |
|---------------------------|------|-----------|---------|--------------|
| MY CANCER PROGRAM | 100% | 100-100 | 8 | 1 |
| MY ACS DIVISION | 86% | 82.6-90.2 | 308 | 88 |
| MY CENSUS REGION | 86% | 82.6-90.2 | 308 | 88 |
| MY COC PROGRAM TYPE | 86% | 84.8-87.6 | 2275 | 226 |
| MY STATE | 84% | 77.9-89.7 | 148 | 38 |
| ALL COC APPROVED PROGRAMS | 86% | 84.9-86.7 | 6319 | 1333 |

Radiation is administered within 1 year (365 days) of diagnosis for women under the age of 70 receiving breast conservation surgery for breast cancer (Accountability)

| COMPARISON TO | EPR% | 95% CI | # CASES | # FACILITIES |
|---------------------------|------|-----------|---------|--------------|
| MY CANCER PROGRAM | 96% | 93.5-99.5 | 141 | 1 |
| MY ACS DIVISION | 94% | 92.9-94.3 | 4224 | 88 |
| MY CENSUS REGION | 94% | 92.9-94.3 | 4224 | 88 |
| MY COC PROGRAM TYPE | 91% | 90.2-91 | 20164 | 226 |
| MY STATE | 93% | 91.7-93.9 | 2041 | 38 |
| ALL COC APPROVED PROGRAMS | 91% | 90.9-91.3 | 60014 | 1333 |

2016 QUALITY IMPROVEMENT MEASURES

Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0, or stage IB - III hormone receptor negative breast cancer (Accountability)

| COMPARISON TO | EPR% | 95% CI | # CASES | # FACILITIES |
|---------------------------|------|-----------|---------|--------------|
| MY CANCER PROGRAM | 88% | 75.3-100 | 25 | 1 |
| MY ACS DIVISION | 94% | 92.7-96.3 | 640 | 88 |
| MY CENSUS REGION | 94% | 92.7-96.3 | 640 | 88 |
| MY COC PROGRAM TYPE | 92% | 91.8-93.4 | 4474 | 226 |
| MY STATE | 91% | 88.3-94.5 | 314 | 38 |
| ALL COC APPROVED PROGRAMS | 93% | 92.2-93.3 | 12254 | 1333 |

Adjuvant chemotherapy is considered or administered within 4 months (120 days) of diagnosis for patients under the age of 80 with AJCC stage III (lymph node positive) colon cancer (Accountability)

| COMPARISON TO | EPR% | 95% CI | # CASES | # FACILITIES |
|---------------------------|------|-----------|---------|--------------|
| MY CANCER PROGRAM | 88% | 72.9-100 | 17 | 1 |
| MY ACS DIVISION | 92% | 89.7-94.5 | 470 | 88 |
| MY CENSUS REGION | 92% | 89.7-94.5 | 470 | 88 |
| MY COC PROGRAM TYPE | 86% | 84.8-87.2 | 3132 | 227 |
| MY STATE | 90% | 85.9-93.7 | 226 | 38 |
| ALL COC APPROVED PROGRAMS | 88% | 87.2-88.4 | 10147 | 1339 |

At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer (Quality Improvement)

| COMPARISON TO | EPR% | 95% CI | # CASES | # FACILITIES |
|---------------------------|------|-----------|---------|--------------|
| MY CANCER PROGRAM | 93% | 87.4-99.6 | 62 | 1 |
| MY ACS DIVISION | 94% | 92.9-94.9 | 2135 | 88 |
| MY CENSUS REGION | 94% | 92.9-94.9 | 2135 | 88 |
| MY COC PROGRAM TYPE | 94% | 93.6-94.4 | 11144 | 227 |
| MY STATE | 94% | 92.4-95.4 | 1006 | 38 |
| ALL COC APPROVED PROGRAMS | 93% | 92.4-93 | 40605 | 1339 |

2016 QUALITY IMPROVEMENT MEASURES

Surgery is not the first course of treatment for cN2, M0 lung cases (Quality Improvement)

| COMPARISON TO | EPR% | 95% CI | # CASES | # FACILITIES |
|---------------------------|------|-----------|---------|--------------|
| MY CANCER PROGRAM | 100% | 100-100 | 21 | 1 |
| MY ACS DIVISION | 92% | 89.9-94.3 | 571 | 88 |
| MY CENSUS REGION | 92% | 89.9-94.3 | 571 | 88 |
| MY COC PROGRAM TYPE | 92% | 90.7-92.7 | 2966 | 227 |
| MY STATE | 94% | 90.9-96.9 | 245 | 38 |
| ALL COC APPROVED PROGRAMS | 93% | 92.2-93.2 | 9146 | 1327 |

Systemic chemotherapy is administered within 4 months to day preoperatively or day of surgery to 6 months postoperatively, or it is considered for surgically resected cases with pathologic lymph node-positive (pN1) and (pN2) NSCLC (Quality Improvement)

| COMPARISON TO | EPR% | 95% CI | # CASES | # FACILITIES |
|---------------------------|------|------------|---------|--------------|
| MY CANCER PROGRAM | 100% | 100-100 | 7 | 1 |
| MY ACS DIVISION | 90% | 86.9-93.7 | 289 | 88 |
| MY CENSUS REGION | 90% | 86.9-93.7 | 289 | 88 |
| MY COC PROGRAM TYPE | 88% | 86.9-89.9 | 1693 | 227 |
| MY STATE | 93% | 89.1-97.5 | 135 | 38 |
| ALL COC APPROVED PROGRAMS | 89% | 88.4 -90.2 | 4317 | 1327 |

2016 QUALITY IMPROVEMENT MEASURES

Preoperative chemo and radiation are administered for clinical AJCC T3N0, T4N0, or Stage III; or Postoperative chemo and radiation are administered within 180 days of diagnosis for clinical AJCC T1-2N0 with pathologic AJCC T3N0, T4N0, or Stage III; or treatment is considered for patients under the age of 80 receiving resection for rectal cancer (Quality Improvement)

| COMPARISON TO | EPR% | 95% CI | # CASES | # FACILITIES |
|---------------------------|------|-----------|---------|--------------|
| MY CANCER PROGRAM | 100% | 100-100 | 17 | 1 |
| MY ACS DIVISION | 85% | 81-88.8 | 332 | 87 |
| MY CENSUS REGION | 85% | 81-88.8 | 332 | 87 |
| MY COC PROGRAM TYPE | 85% | 83.4-86.4 | 2307 | 227 |
| MY STATE | 86% | 80.9-91.3 | 173 | 37 |
| ALL COC APPROVED PROGRAMS | 87% | 85.9-87.7 | 5992 | 1321 |

At least 2 lymph nodes are removed in patients under 80 undergoing partial or radical cystectomy (Surveillance)

| COMPARISON TO | EPR% | 95% CI | # CASES | # FACILITIES |
|---------------------------|------|------------|---------|--------------|
| MY CANCER PROGRAM | 100% | 100-100 | 5 | 1 |
| MY ACS DIVISION | 97% | 94.5-99.9 | 143 | 87 |
| MY CENSUS REGION | 97% | 94.5-99.9 | 143 | 87 |
| MY COC PROGRAM TYPE | 96% | 94.6-96.8 | 1308 | 225 |
| MY STATE | 97% | 94.1-100 | 79 | 38 |
| ALL COC APPROVED PROGRAMS | 92% | 91.4 -93.6 | 2159 | 1315 |

2016 QUALITY IMPROVEMENT MEASURES

Chemotherapy and/or radiation administered to patients with Stage IIIC or IV endometrial cancer (Surveillance)

| COMPARISON TO | EPR% | 95% CI | # CASES | # FACILITIES |
|---------------------------|------|------------|---------|--------------|
| MY CANCER PROGRAM | 100% | 100-100 | 4 | 1 |
| MY ACS DIVISION | 91% | 86.2-95.6 | 143 | 86 |
| MY CENSUS REGION | 91% | 86.2-95.6 | 143 | 86 |
| MY COC PROGRAM TYPE | 87% | 84.9-88.5 | 1408 | 223 |
| MY STATE | 87% | 77.7-95.9 | 53 | 37 |
| ALL COC APPROVED PROGRAMS | 83% | 82.2 -84.8 | 2955 | 1268 |

At least 15 regional lymph nodes are removed and pathologically examined for resected gastric cancer (Quality Improvement)

| COMPARISON TO | EPR% | 95% CI | # CASES | # FACILITIES |
|---------------------------|------|-----------|---------|--------------|
| MY CANCER PROGRAM | 87% | 64.6-100 | 8 | 1 |
| MY ACS DIVISION | 70% | 62.1-77.3 | 142 | 84 |
| MY CENSUS REGION | 70% | 62.1-77.3 | 142 | 84 |
| MY COC PROGRAM TYPE | 71% | 68.6-73.6 | 1253 | 226 |
| MY STATE | 76% | 66.1-85.1 | 78 | 37 |
| ALL COC APPROVED PROGRAMS | 65% | 62.8-66.6 | 2526 | 1242 |



Patients and families trust UMass Memorial Medical Center as the region's leading academic medical center, committed to improving the health of our communities in Central Massachusetts. With our partner, the University of Massachusetts Medical School, we are committed to excellence in primary and specialty care, community service, teaching and research. The Medical Center offers advanced technology and support services for patients and families, providing the region with specialists renowned for their expertise in caring for adults and children.

Visit www.umassmemorial.org. General information: 508-334-1000



UMass Memorial Health Care is the largest not-for-profit health care system in Central Massachusetts with more than 13,000 employees and 1,700 physicians, many of whom are members of UMass Memorial Medical Group. Our member hospitals and entities include UMass Memorial HealthAlliance-Clinton Hospital, UMass Memorial – Marlborough Hospital, UMass Memorial Medical Center and UMass Memorial – Community Healthlink, our behavioral health agency. With our teaching and research partner, the University of Massachusetts Medical School, our extensive primary care network and our cancer, diabetes, heart and vascular, orthopedic and surgery programs, UMass Memorial delivers safe, high-quality and compassionate care.

Visit www.umassmemorialhealthcare.org.



To find a physician in your community, call 855-UMASS-MD (855-862-7763).

UMass Memorial Medical Center - University Campus
55 Lake Avenue North, Worcester, MA 01655